Loading...
XNAS
FLGT
Market cap663mUSD
Jun 10, Last price  
21.79USD
1D
-0.11%
1Q
24.63%
Jan 2017
88.29%
IPO
136.28%
Name

Fulgent Genetics Inc

Chart & Performance

D1W1MN
P/E
P/S
2.34
EPS
Div Yield, %
Shrs. gr., 5y
10.08%
Rev. gr., 5y
54.19%
Revenues
283m
-1.99%
01,278,0009,576,00018,276,00018,730,00021,357,00032,528,000421,712,000992,584,000618,968,000289,213,000283,470,000
Net income
-43m
L-74.55%
104,339,000-4,283,000-8,314,000-5,388,000-2,661,000-4,489,000366,000214,310,000507,364,000143,403,000-167,825,000-42,708,000
CFO
21m
-22.01%
534,250,000-4,397,000-969,0004,405,0001,331,000-675,0005,517,000140,628,000538,577,000253,520,00027,003,00021,060,000
Earnings
Jul 31, 2025

Profile

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
IPO date
Sep 28, 2016
Employees
1,012
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
283,470
-1.99%
289,213
-53.27%
618,968
-37.64%
Cost of revenue
349,423
356,663
430,969
Unusual Expense (Income)
NOPBT
(65,953)
(67,450)
187,999
NOPBT Margin
30.37%
Operating Taxes
(8,136)
1,154
42,102
Tax Rate
22.39%
NOPAT
(57,817)
(68,604)
145,897
Net income
(42,708)
-74.55%
(167,825)
-217.03%
143,403
-71.74%
Dividends
Dividend yield
Proceeds from repurchase of equity
(3,124)
(27,792)
(74,306)
BB yield
0.56%
3.23%
8.06%
Debt
Debt current
412
5,140
20,638
Long-term debt
5,563
21,215
25,564
Deferred revenue
(12,167)
Other long-term liabilities
11,536
10,951
(32,016)
Net debt
(252,131)
(841,808)
(1,145,714)
Cash flow
Cash from operating activities
21,060
27,003
253,520
CAPEX
(22,207)
(22,207)
(18,775)
Cash from investing activities
38,898
38,898
(261,314)
Cash from financing activities
(47,785)
(47,785)
(77,141)
FCF
(74,913)
(98,682)
174,187
Balance
Cash
258,106
424,154
852,883
Long term investments
444,009
339,033
Excess cash
243,932
853,702
1,160,968
Stockholders' equity
586,033
631,568
795,675
Invested Capital
897,174
527,920
434,751
ROIC
31.86%
ROCE
14.57%
EV
Common stock shares outstanding
30,235
29,784
30,964
Price
18.47
-36.11%
28.91
-2.92%
29.78
-70.39%
Market cap
558,440
-35.14%
861,055
-6.62%
922,108
-70.41%
EV
302,240
16,432
(208,031)
EBITDA
(43,721)
(35,693)
220,661
EV/EBITDA
Interest
170
5,498
Interest/NOPBT
2.92%